期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 165, 期 3, 页码 603-621出版社
WILEY
DOI: 10.1111/j.1476-5381.2011.01528.x
关键词
obesity; adipokine; small lipid-binding protein; lipotoxicity; endothelial cell; vascular inflammation; atherosclerosis; therapeutic targets; drug discovery
资金
- Research Grant Council of Hong Kong [777208 M, 780410 M, HKU 2/07C, HKU4/CRF/10]
Dysregulated production of adipokines from adipose tissue plays a critical role in the development of obesity-associated cardiovascular abnormalities. A group of adipokines, including adipocyte fatty acid binding protein (A-FABP) and lipocalin-2, possess specific lipid-binding activity and are up-regulated in obese human subjects and animal models. They act as lipid chaperones to promote lipotoxicity in endothelial cells and cause endothelial dysfunction under obese conditions. However, different small lipid-binding proteins modulate the development of vascular complications in distinctive manners, which are partly attributed to their specialized structural features and functionalities. By focusing on A-FABP and lipocalin-2, this review summarizes recent advances demonstrating the causative roles of these newly identified adipose tissue-derived lipid chaperones in obesity-related endothelial dysfunction and cardiovascular complications. The specific lipid-signalling mechanisms mediated by these two proteins are highlighted to support their specialized functions. In summary, A-FABP and lipocalin-2 represent potential therapeutic targets to design drugs for preventing vascular diseases associated with obesity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据